In the AuToDeCRA study, the team showed that they were able to make TolDC from white blood cells collected from patients and that it was safe to inject into the knee joint of people with active Rheumatoid Arthritis. However, the study did not tell us whether an injection into a joint was the best way to deliver the experimental treatment to people. 

In AuToDeCRA-2, we will compare three different delivery methods and look to identify changes in the immune system when TolDC are administered to participants with RA.

We will also be looking for signs of improvement in participant's RA when given TolDC compared to standard care while collecting further evidence of safety and acceptability from participants.